--- title: "Dyadic International (DYAI) news: delisting and offering" url: "https://aibio.space/companies/dyadic-international/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "DYAI delisting, offering and Nasdaq notice news: Dyadic International gets Nasdaq delisting notice over bid price, plans hearing. Dyadic International, Inc." --- DYAI Dyadic International, Inc. NASDAQ · United States # Dyadic International (DYAI) news DYAI delisting, offering and Nasdaq notice news Listings · 2026-06-18 ## [Dyadic International gets Nasdaq delisting notice over bid price, plans hearing](https://aibio.space/news/dyadic-international-gets-nasdaq-delisting-notice-bid-price-plans/) Nasdaq started a process that could lead to delisting after Dyadic missed the June 17, 2026 deadline to meet the $1.00 minimum bid price. The company plans to request a hearing, and the request automatically stays any delisting action until the panel decides. ## Latest Dyadic International news 1. 2026-03-30 Listings [Dyadic International gets Nasdaq deficiency notice under Rule 5550(b) minimum listing requirements](https://aibio.space/news/dyadic-international-gets-nasdaq-deficiency-notice-under-rule-5550/) Dyadic received a Nasdaq notice on March 27, 2026 that it is out of compliance with Listing Rule 5550(b). It has until May 11, 2026 to submit a plan to regain compliance, and a separate bid price deadline of June 17, 2026 also stands. 2. 2025-07-30 Financings [Dyadic International prices 6,052,000-share offering at $0.95, below last trade](https://aibio.space/news/dyadic-international-prices-6-052-000-share-offering-0-95-below-last/) Gross proceeds would be $5,749,400. The price compares with a last reported sale of $1.1750 on July 29, 2025. An executive agreed to buy 26,000 shares. ## Dyadic International at a glance - **Ticker**: DYAI - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $3.1 million ### Related companies - [Polaryx Therapeutics](https://aibio.space/companies/polaryx-therapeutics/) NASDAQ: PLYX - [Dermata Therapeutics](https://aibio.space/companies/dermata-therapeutics/) NASDAQ: DRMA - [RenovoRx](https://aibio.space/companies/renovorx/) NASDAQ: RNXT - [Nutriband](https://aibio.space/companies/nutriband/) NASDAQ: NTRB - [Rockwell Medical](https://aibio.space/companies/rockwell-medical/) NASDAQ: RMTI - [Endovia Health Sciences](https://aibio.space/companies/endovia-health-sciences/) AMEX: EDVA - [Celularity](https://aibio.space/companies/celularity/) NASDAQ: CELU - [Apollomics](https://aibio.space/companies/apollomics/) NASDAQ: APLM ### Also on NASDAQ - [Cullinan Therapeutics](https://aibio.space/companies/cullinan-therapeutics/) CGEM - [Guardant Health](https://aibio.space/companies/guardant-health/) GH - [Telomir Pharmaceuticals](https://aibio.space/companies/telomir-pharmaceuticals/) TELO - [NuCana](https://aibio.space/companies/nucana/) NCNA - [PepGen](https://aibio.space/companies/pepgen/) PEPG - [Phio Pharmaceuticals](https://aibio.space/companies/phio-pharmaceuticals/) PHIO ## Dyadic International annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$3.1 million](https://www.sec.gov/Archives/edgar/data/1213809/000149315226012672/) | [$3.5 million](https://www.sec.gov/Archives/edgar/data/1213809/000149315226012672/) | | Research and development | [$2.2 million](https://www.sec.gov/Archives/edgar/data/1213809/000149315226012672/) | [$2.0 million](https://www.sec.gov/Archives/edgar/data/1213809/000149315226012672/) | | Net income (loss) | [-$7.4 million](https://www.sec.gov/Archives/edgar/data/1213809/000149315226012672/) | [-$5.8 million](https://www.sec.gov/Archives/edgar/data/1213809/000149315226012672/) | | Cash from operations | [-$5.7 million](https://www.sec.gov/Archives/edgar/data/1213809/000149315226012672/) | [-$4.0 million](https://www.sec.gov/Archives/edgar/data/1213809/000149315226012672/) | | Cash and equivalents | [$4.6 million](https://www.sec.gov/Archives/edgar/data/1213809/000149315226037258/) | [$6.5 million](https://www.sec.gov/Archives/edgar/data/1213809/000149315226012672/) | | Short-term investments | [$2.7 million](https://www.sec.gov/Archives/edgar/data/1213809/000149315226037258/) | [$2.8 million](https://www.sec.gov/Archives/edgar/data/1213809/000149315226012672/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $1.4 million, plus short-term investments of $1.7 million, $3.1 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Dyadic International Was Dyadic International delisted? Our latest story on this, dated Jun 18, 2026: "Dyadic International gets Nasdaq delisting notice over bid price, plans hearing". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/dyadic-international-gets-nasdaq-delisting-notice-bid-price-plans/). Has Dyadic International raised money recently? Our latest story on this, dated Jul 30, 2025: "Dyadic International prices 6,052,000-share offering at $0.95, below last trade". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/dyadic-international-prices-6-052-000-share-offering-0-95-below-last/). Has Dyadic International received a Nasdaq deficiency notice? Our latest story on this, dated Mar 30, 2026: "Dyadic International gets Nasdaq deficiency notice under Rule 5550(b) minimum listing requirements". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/dyadic-international-gets-nasdaq-deficiency-notice-under-rule-5550/). What is the ticker symbol of Dyadic International? Dyadic International, Inc. trades under the ticker DYAI on NASDAQ. Where is Dyadic International listed? Dyadic International, Inc. is listed on NASDAQ. What is the SEC CIK of Dyadic International? The SEC Central Index Key (CIK) for Dyadic International, Inc. is 1213809. Its filings are on SEC EDGAR. How many shares does Dyadic International have outstanding? 36,438,703 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-12. Which country or territory is Dyadic International listed under? Our directory records Dyadic International, Inc. under United States. What does Dyadic International do? Our directory classifies Dyadic International, Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline. What is the ISIN of Dyadic International? The ISIN recorded for Dyadic International, Inc. is US26745T1016. Does aibio.space cover Dyadic International? aibio.space lists Dyadic International, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Dyadic International incorporated? SEC records list its state or country of incorporation as DE. What was Dyadic International's revenue last year? $3.1 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Dyadic International profitable? Dyadic International, Inc. reported a net loss of $7.4 million for the fiscal year ended Dec 31, 2025, and used $5.7 million of cash in operations, per its annual report to the SEC. How much does Dyadic International spend on research and development? $2.2 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Dyadic International Members talk about Dyadic International (DYAI). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Dyadic International, newest first. Each line links the filing it comes from. 1. 2026-09-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1213809/000149315226044398/form8-k.htm) 2. 2026-08-13 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1213809/000149315226037870/form424b5.htm) 3. 2026-08-12 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1213809/000149315226037258/form10-q.htm) 4. 2026-06-22 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1213809/000149315226029504/form8-k.htm) 5. 2026-06-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1213809/000149315226029214/form8-k.htm) 6. 2026-05-12 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1213809/000149315226022505/formdef14a.htm) 7. 2026-05-01 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1213809/000149315226020913/formpre14a.htm) 8. 2026-03-30 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1213809/000149315226013405/form8-k.htm) 9. 2026-03-06 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1213809/000149315226009176/form424b5.htm) 10. 2025-12-29 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1213809/000149315225029141/form8-k.htm) 11. 2025-12-29 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1213809/000149315225029351/form8-k.htm) 12. 2025-10-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1213809/000149315225017306/ex99-1.htm) 13. 2025-07-30 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1213809/000164117225021545/form424b5.htm) 14. 2025-07-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1213809/000164117225020728/form8-k.htm) 15. 2025-06-27 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1213809/000143774925021420/dyai20250626_8k.htm) 16. 2025-05-05 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1213809/000143774925014571/dyai20250504_8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:DYAI on TradingView](https://www.tradingview.com/symbols/NASDAQ-DYAI/). ## SEC filings and registration - **SEC name**: Dyadic International Inc - **CIK**: 1213809 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: DYAI (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 1044 NORTH U.S. HIGHWAY ONE, JUPITER, FL, 33477 - **Phone**: 561-743-8333 - **Shares outstanding**: 36,438,703 as of 2026-08-11 (10-Q filed 2026-08-12) - **Former names**: CCP WORLDWIDE INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1213809/000149315226044398/form8-k.htm) filed 2026-09-25 - [S-1](https://www.sec.gov/Archives/edgar/data/1213809/000149315226042435/forms-1.htm) filed 2026-09-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1213809/000149315226038039/form8-k.htm) filed 2026-08-14 - [424B5](https://www.sec.gov/Archives/edgar/data/1213809/000149315226037870/form424b5.htm) filed 2026-08-13 - [10-Q](https://www.sec.gov/Archives/edgar/data/1213809/000149315226037258/form10-q.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1213809/000149315226037257/form8-k.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1213809/000149315226034475/form8-k.htm) filed 2026-07-24 - [8-K](https://www.sec.gov/Archives/edgar/data/1213809/000149315226029504/form8-k.htm) filed 2026-06-22 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001213809), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Dyadic International, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker DYAI, recorded under United States. The directory classifies it as Biopharma / pharmaceuticals. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Dyadic International, Inc. - **Ticker**: DYAI - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biopharma / pharmaceuticals - **ISIN**: US26745T1016 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-DYAI/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/dyadic-international/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Dyadic International (DYAI) news: delisting and offering", 2026-10-31, https://aibio.space/companies/dyadic-international/